ROCHESTER, N.Y., March 15, 2012 (GLOBE NEWSWIRE) -- NaturalNano, Inc. (OTCBB:NNAN) (www.naturalnano.com) announced today that Dr. Michael King of Cornell University published his new technique for the isolation of circulating tumor cells (CTC) using NaturalNano's halloysite nanotubes. Dr. King's report explains his lab's recent work showing how thin coatings of naturally-forming halloysite nanotubes can greatly improve the efficiency of CTC capture from patient blood samples under flow.
Dr. King, an associate professor of Biomedical Engineering at Cornell University, states, "The isolation of circulating tumor cells (CTCs) from blood samples can be targeted more effectively by incorporation of halloysite nanotubes (HNT) onto the surface of flow devices used to capture CTCs in blood." King continued, "We present a new lab protocol that utilizes off-the-shelf materials and standard equipment, so clinical and research labs will be able to utilize the method without difficulty."
James Wemett, NaturalNano CEO, said, "We are pleased to have Dr. King's work with our HNT materials published. Wemett continued,"Dr. King's work with HNT continues to build on our understanding of the potential role that HNT may play in life science applications."
The abstract can be viewed at the following link: http://www.clinchem.org/content/early/2012/02/16/clinchem.2011.176669.abstract">http://www.clinchem.org/content/early/2012/02/16/clinchem.2011.176669.abstract or contact Dr. King for further details.
About NaturalNano, Inc.
NaturalNano, Inc. (OTCBB:NNAN) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. www.naturalnano.com
Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.